CGON241220C30000
- 0.10
- 0.000.00%
CG Oncology Newsroom
RBC Capital Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $66
RBC Capital Reiterates Outperform on CG Oncology, Maintains $66 Price Target
A Quick Look at Today's Ratings for CG Oncology(CGON.US), With a Forecast Between $55 to $86
Analysts Offer Insights on NA Companies: Rubrik, Inc. Class A (RBRK) and CG Oncology, Inc. (CGON)
CG Oncology Analyst Ratings
Promising Clinical Results and Strategic Positioning: CG Oncology Recommended as a Buy
Analysts' Top NA Picks: GE Vernova Inc. (GEV), CG Oncology, Inc. (CGON)
RBC Capital Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $66
Morgan Stanley Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $55
CG Oncology Analyst Ratings
CG Oncology Price Target Maintained With a $75.00/Share by HC Wainwright & Co.
Analysts Offer Insights on NA Companies: CG Oncology, Inc. (CGON), Smith Douglas Homes Corp. Class A (SDHC) and Palmer Square Capital BDC Inc. (PSBD)
LifeSci Capital Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $86
H.C. Wainwright Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $75
CG Oncology Price Target Maintained With a $75.00/Share by HC Wainwright & Co.
LifeSci Capital Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $86
CG Oncology's Strategic Growth and Promising Therapeutic Developments Reinforce Buy Rating
Morgan Stanley Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $55
CG Oncology Analyst Ratings
UBS Initiates CG Oncology(CGON.US) With Buy Rating, Announces Target Price $60